AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for Heart Failure

Share this

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for Heart Failure


  • The approval is based on P-III DAPA-HF study involves assessing of Forxiga (10mg) + SOC vs PBO +SOC in 4744 patients with heart failure and reduced ejection fraction (LVEF ≤ 40%) with/out T2D
  • Results: reduction in risk of the composite outcome by 26%- with both components of the 1EPs (first occurrence of a worsening HF event or CV death) contributed benefit to the overall effect.
  • Forxiga is the first SGLT2 inhibitor approved in the EU for HFrEF in adult patients with/out T2D. The therapy is currently being evaluated for HFpEF in P-III DELIVER study with its anticipated results in H2’21

  Ref: AstraZeneca | Image: New Europe

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions